Biogen Inc logo

Biogen Inc

$ 301.24 (0%) Sep 23
On watch
P/E:
14.11
P/B:
2.42
Market Cap:
$ 28.70B
Enterprise V:
$ 31.45B
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap $:
28.70B
PE Ratio:
14.11
Avg Vol (2-Month):
-
Enterprise Value $:
31.45B
PB Ratio:
2.42
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Name Current Vs Industry Vs History
Cash-To-Debt 0.64
Equity-to-Asset 0.47
Debt-to-Equity 0.64
Debt-to-EBITDA 2.42
Interest Coverage 11.01
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.13
Distress
Grey
Safe
Beneish M-Score -2.61
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.94
Quick Ratio 1.68
Cash Ratio 0.96
Days Inventory 195.81
Days Sales Outstanding 70.16
Days Payable 67.43

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 9.3

Financials (Next Earnings Date:2022-10-20 Est.)

LTS:0R1B's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 10,633.6
EPS (TTM) ($) 14.02
Beta -0.15
Volatility % 11.64
14-Day RSI 0
14-Day ATR ($) 0
20-Day SMA ($) 301.24
12-1 Month Momentum % 0
52-Week Range ($) 301.24 - 301.24
Shares Outstanding (Mil) 145.11

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biogen Inc Filings

Document Form Filing Date
No Filing Data

Biogen Inc Analysis

Share your research